Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Ítems similars

• Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
  per: Degryse, S, et al.
  Publicat: (2018)
• Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL
  per: Degryse, Sandrine, et al.
  Publicat: (2018)
• JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
  per: Degryse, Sandrine, et al.
  Publicat: (2015)
• JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
  per: Govaerts, Inge, et al.
  Publicat: (2019)
• Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
  per: Murray, Heather C., et al.
  Publicat: (2020)